 LEXINGTON, Mass., June 11, 2021 PRNewswire -- Curis, Inc. NASDAQ: CRIS, a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated data from its ongoing Phase 12 open-label, single arm, dose escalation and expansion trial of CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in patients with acute myeloid leukemia AML or high-risk myelodysplastic syndromes MDS at the European Hematology Association 2021 Virtual Congress EHA. 